R&D Trends

IBM, New York Genome Center partner on open cancer data repository

Monday, March 7, 2016

The New York Genome Center and IBM are collaborating to create a comprehensive and open repository of genetic data to accelerate cancer research and scale access to precision medicine using cognitive insights from IBM Watson. Analyzing this data alongside the medical community’s growing knowledge about cancer could help accelerate the ability of doctors to deliver personalized treatment to individual patients.

[Read More]

Andrew Lloyd & Associates, Adebiotech partner for innovation

Wednesday, March 2, 2016

Andrew Lloyd & Associates (ALA), an international public relations group for companies and organizations working in life sciences and innovative technologies, and Adebiotech, an independent cross-disciplinary think-tank for biotechnology in France, have signed a partnership agreement to promote interdisciplinary discussion and innovation in the field of biotechnology. In particular, this partnership aims to raise awareness of Adebiotech’s activities amongst specialist audiences interested in developments concerning human and animal health, the environment, energy, food processing, cosmetics, processes and industrial systems, amongst others.

[Read More]

Report: Breast cancer has over 1,000 drugs in development

Tuesday, March 1, 2016

The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.

[Read More]

JDRF, Sanofi expand research collaboration for insulin-dependent diabetes

Tuesday, March 1, 2016

JDRF, a global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi U.S. Services, a subsidiary of Sanofi, have entered into new agreements with four research organizations under their joint research collaboration to support development of glucose responsive insulins (GRIs), an alternate class of therapies that is expected to improve the treatment of insulin-dependent diabetes, particularly T1D.

[Read More]

Baxalta, Precision BioSciences ink $1.6B immuno-oncology collaboration

Friday, February 26, 2016

Baxalta, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, a genome editing company, have announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers.

[Read More]

CHOP, Seven Bridges form Cavatica for pediatric cancer genomics data

Friday, February 26, 2016

The Children’s Hospital of Philadelphia (CHOP), the lead operations center for the Childhood Brain Tumor Tissue Consortium (CBTTC), and Seven Bridges, a biomedical data analysis company, have announced the joint development of Cavatica, a new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric cancer patient genomics data. Cavatica will support CHOP’s commitment to the White House Precision Medicine Initiative (PMI) through the newly launched Center for Data Driven Discovery in Biomedicine (D3b), located at CHOP. 

[Read More]

Gilead launches HIV cure grants program

Tuesday, February 23, 2016

Gilead Sciences will be providing grants for up to three years to academic institutions, nonprofit organizations and community groups engaged in HIV cure activities. The unrestricted grants will be awarded to organizations with a track record of excellence in results-driven research.

[Read More]

Bristol-Myers Squibb, Dana-Farber partner on immuno-oncology research program

Tuesday, February 16, 2016

Bristol-Myers Squibb and Dana-Farber Cancer Institute have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. Dana-Farber Cancer Institute is the latest academic-based cancer center to join the I-O RPM program, which is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

[Read More]